Diverse customers have common compliance goals
JERSEY CITY, N.J. – TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced it has added four new customers from across the life sciences industry. The new customers have all contracted for PharmaCM, TrialScope’s SaaS-based clinical trial disclosure platform.
The customers represent a broad cross-section of the life sciences marketplace including a small biopharmaceutical company specializing in orphan drugs, two top twenty, global pharmaceutical companies and a company with a combination portfolio of products including generics and specialty medicines.
Mike Forgash, CEO, noted, “The diversity of the customer base confirms the effectiveness of our product strategy. In the last year, we have focused on simplifying both our systems and implementation approach to clinical trial disclosure so that the PharmaCM suite can add value for small, growing teams and medium sized teams as well as large, global teams. Compliance is the common goal, but how you get there varies from team to team. Our goal is to support clinical trial transparency efforts, regardless of team size, functional boundaries or geography.”
“We have recently seen a strong interest in our solutions from small and mid-size organizations,” added Thomas Wicks, chief strategy officer. “They understand the benefits of our transparency solution and the risks of non-compliance and are looking to “get it right” early in the process. These companies value our global compliance management approach to clinical trial disclosure and want to leverage our expertise and technologies to develop their capabilities.”
TrialScope is employing its Rapid Path to Compliance engagement methodology to ensure that the growing customer list benefits from best practices and lessons learned from our customers and implemented by our subject matter experts.
About TrialScope
TrialScope, recognized by CIOReview in their 2016 List of the 20 Most Promising Pharma and Life Sciences Tech Solution Providers, simplifies the complexities of clinical trial transparency performance. TrialScope’s award-winning, proven solutions have been implemented successfully and rigorously tested in the most complex environments and are managing disclosures for roughly 30% of industry sponsored clinical trials. The company’s market-driven solutions and expertise enable sponsors to improve performance, mitigate compliance risk, and ultimately optimize efficiencies with clinical content lifecycle management tools, expertise and processes. TrialScope technologies are offered via a validation-ready SaaS platform hosted in a private cloud.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.